Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
August 10, 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today additional positive data from its phase I/II clinical trial of...